| Identification | Back Directory | [Name]
ARS-1323 | [CAS]
1698024-73-5 | [Synonyms]
CPD2015
ARS-1323
ARS1323;ARS 1323;ARS-1323
Inhibitor,Ras,ARS1323,ARS 1323,inhibit,ARS-1323
2-Propen-1-one, 1-[4-[6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)-4-quinazolinyl]-1-piperazinyl]- | [Molecular Formula]
C21H17ClF2N4O2 | [MOL File]
1698024-73-5.mol | [Molecular Weight]
430.84 |
| Chemical Properties | Back Directory | [Boiling point ]
614.7±55.0 °C(Predicted) | [density ]
1.434±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 125 mg/mL (290.13 mM) | [form ]
Solid | [pka]
6.03±0.35(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
ARS-1620, is an atropisomeric selective KRASG12C inhibitor with desirable pharmacokinetics. | [Definition]
ChEBI: ARS-1620 is a qinazoline derivative carrying chloro and fluoro substituents at positions 6 and 8 respectively, a 2-fluoro-6-hydroxyphenyl group at position 7, and a 4-(prop-2-enoyl)piperazin-1-yl group at position 4. A potent, selective, and orally bioavailable covalent KRAS-G12C inhibitor, it inhibits the protein coding gene KRAS (Kirsten rat sarcoma virus) with high potency in cells and animals. It has a role as an inhibitor, an antiviral agent and an antineoplastic agent. | [IC 50]
KRas G12C |
|
|